Intrinsic Imaging Awarded Important Clinical Trial for the Evaluation of Breast Disease

Breast imaging expertise and radiologist reviews support a clinical trial evaluating the safety and effectiveness of a product.

Bolton, MA / San Antonio, TX

Bolton, MA / San Antonio, TX — January 10, 2012 — Intrinsic Imaging, an ISO 9001:2008 certified medical imaging core lab providing clinical image management and radiological review services in support of pharmaceutical, biotechnology, medical device and clinical research organizations, announces today that it was recently awarded an important clinical trial for the evaluation of breast cancer.

Over the duration of this clinical trial, Intrinsic Imaging will provide its wealth of breast imaging and clinical trial expertise, as well as provide its team of over 60 subspecialized radiologists, to evaluate the product's clinical safety and effectiveness. This trial, which will be managed from Intrinsic Imaging's Bolton and San Antonio locations, consists of nearly 3,000 reviews.

"Intrinsic Imaging's board-certified, breast imaging radiologists currently manage over 150,000 breast related images annually and are responsible for the full complement of imaging and intervention as it relates to the evaluation, diagnosis, prognosis and progression of breast disease. " said Richard Benedikt, M.D., MBA, Medical Director, Breast Imaging at Intrinsic Imaging. "Our team has extensive expertise in the field of breast cancer and routinely performs all elements of breast cancer imaging including but not limited to full field digital mammography (FFDM) with Computer Assisted Detection (CAD), whole breast ultrasound, MRI, PET/CT, and nuclear medicine Imaging."

The American Cancer Society estimates that in 2012 about 577,190 Americans are expected to die of cancer, more than 1,500 people a day. Breast cancer, defined as a malignant tumor that starts in the cells of the breast and may eventually invade surrounding tissues or metastasize to distant areas of the body, is the most common cancer among American women. In 2012, approximately 226,870 new cases of breast cancer are expected to be diagnosed among women.

"Today more and more breast cancer trials are underway and are becoming increasingly complex. Intrinsic Imaging is proud to contribute our operational and therapeutic expertise in breast cancer clinical trials and to contribute to the successful evaluation of a new product's clinical safety and effectiveness." said Todd A. Joron, BSc. MBA, President and Chief Operating Officer, Intrinsic Imaging.

About Intrinsic Imaging, LLC

Intrinsic Imaging is an ISO certified medical imaging CRO and imaging core lab providing comprehensive services in support of Phase I-IV clinical trials and Class I, II, III medical device trials. Intrinsic Imaging is also a world leader in conducting Artificial Intelligence studies. With its team of more than 750 board-certified and fellowship-trained physicians, Intrinsic Imaging's team has sub-specialization in all therapeutic areas, including Cardiovascular, Central Nervous System,Gastroenterology, Musculoskeletal, Oncology and Ophthalmology. Certified by the British Standards Institution (BSI), Intrinsic Imaging is the only company in the world to hold five ISO certifications specifically for providing imaging core lab services on clinical trials. For more information, please visit www.IntrinsicImaging.com.

Contact:

Intrinsic Imaging, LLC
580 Main St., Suite 210
Bolton, MA, 01740, USA
+1 978-616-4650
Contact@IntrinsicImaging.com